Bio-Rad Laboratories Future Growth
Future criteria checks 3/6
Bio-Rad Laboratories is forecast to grow earnings and revenue by 51.6% and 3.6% per annum respectively. EPS is expected to grow by 51.5% per annum. Return on equity is forecast to be 5.5% in 3 years.
Key information
51.6%
Earnings growth rate
51.5%
EPS growth rate
| Life Sciences earnings growth | 17.6% |
| Revenue growth rate | 3.6% |
| Future return on equity | 5.5% |
| Analyst coverage | Good |
| Last updated | 06 Sep 2024 |
Recent future growth updates
Recent updates
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08
Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,796 | 313 | N/A | N/A | 5 |
| 12/31/2025 | 2,691 | 274 | N/A | N/A | 6 |
| 12/31/2024 | 2,579 | 236 | N/A | N/A | 6 |
| 6/30/2024 | 2,563 | -1,326 | 177 | 346 | N/A |
| 3/31/2024 | 2,605 | -322 | 185 | 347 | N/A |
| 12/31/2023 | 2,671 | -637 | 218 | 375 | N/A |
| 9/30/2023 | 2,720 | -159 | 223 | 374 | N/A |
| 6/30/2023 | 2,769 | -428 | 153 | 287 | N/A |
| 3/31/2023 | 2,779 | -191 | 125 | 242 | N/A |
| 12/31/2022 | 2,802 | -3,628 | 80 | 194 | N/A |
| 9/30/2022 | 2,805 | -6,021 | 152 | 286 | N/A |
| 6/30/2022 | 2,871 | -1,930 | 364 | 505 | N/A |
| 3/31/2022 | 2,896 | -91 | 459 | 606 | N/A |
| 12/31/2021 | 2,923 | 4,254 | 536 | 670 | N/A |
| 9/30/2021 | 2,980 | 6,659 | 670 | 783 | N/A |
| 6/30/2021 | 2,880 | 4,045 | 590 | 689 | N/A |
| 3/31/2021 | 2,701 | 4,098 | 533 | 626 | N/A |
| 12/31/2020 | 2,546 | 3,814 | 480 | 585 | N/A |
| 9/30/2020 | 2,380 | 3,521 | 378 | 450 | N/A |
| 6/30/2020 | 2,294 | 1,947 | 323 | 414 | N/A |
| 3/31/2020 | 2,329 | 1,579 | 383 | 478 | N/A |
| 12/31/2019 | 2,312 | 1,759 | 368 | 458 | N/A |
| 9/30/2019 | 2,304 | 377 | 272 | 403 | N/A |
| 6/30/2019 | 2,289 | 905 | 251 | 366 | N/A |
| 3/31/2019 | 2,292 | 574 | 169 | 288 | N/A |
| 12/31/2018 | 2,289 | 366 | 156 | 285 | N/A |
| 9/30/2018 | 2,294 | 1,277 | 148 | 250 | N/A |
| 6/30/2018 | 2,283 | 1,030 | 116 | 216 | N/A |
| 3/31/2018 | 2,212 | 767 | N/A | 201 | N/A |
| 12/31/2017 | 2,160 | 122 | N/A | 104 | N/A |
| 9/30/2017 | 2,110 | 17 | N/A | 130 | N/A |
| 6/30/2017 | 2,085 | 13 | N/A | 153 | N/A |
| 3/31/2017 | 2,097 | 26 | N/A | 168 | N/A |
| 12/31/2016 | 2,068 | 26 | N/A | 216 | N/A |
| 9/30/2016 | 2,067 | 98 | N/A | 157 | N/A |
| 6/30/2016 | 2,028 | 97 | N/A | 188 | N/A |
| 3/31/2016 | 2,018 | 108 | N/A | 149 | N/A |
| 12/31/2015 | 2,019 | 109 | N/A | 186 | N/A |
| 9/30/2015 | 2,047 | 103 | N/A | 190 | N/A |
| 6/30/2015 | 2,108 | 97 | N/A | 199 | N/A |
| 3/31/2015 | 2,139 | 100 | N/A | 237 | N/A |
| 12/31/2014 | 2,175 | 89 | N/A | 273 | N/A |
| 9/30/2014 | 2,179 | 80 | N/A | 304 | N/A |
| 6/30/2014 | 2,154 | 61 | N/A | 268 | N/A |
| 3/31/2014 | 2,142 | 64 | N/A | 211 | N/A |
| 12/31/2013 | 2,133 | 78 | N/A | 169 | N/A |
| 9/30/2013 | 2,104 | 91 | N/A | 194 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: BIO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BIO is expected to become profitable in the next 3 years.
Revenue vs Market: BIO's revenue (3.6% per year) is forecast to grow slower than the US market (8.5% per year).
High Growth Revenue: BIO's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIO's Return on Equity is forecast to be low in 3 years time (5.5%).